Plain-English translation of NCT06102759 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a combination of three medications — Adebrelimab (a type of immunotherapy), Fruquintinib (a targeted therapy), and Paclitaxel (a chemotherapy drug) — for people with advanced stomach cancer who have already tried one line of immunotherapy treatment. The goal is to see whether combining these three medications together can help the cancer respond better than traditional second-line treatment alone.
Many patients with advanced stomach cancer receive immunotherapy as their first treatment, but some patients don't benefit enough from that approach. This trial is looking for a better second-line option by combining immunotherapy with other types of cancer-fighting drugs to improve outcomes for patients whose first treatment didn't work as well as hoped.
You likely qualify if…
You likely don't qualify if…
You would receive three medications given together every three weeks: an injection of Adebrelimab, an oral pill of Fruquintinib (taken twice daily for 14 days), and an intravenous infusion of Paclitaxel. You would have regular clinic visits for blood tests and imaging scans to monitor how the cancer responds and how you are tolerating the treatment. The trial expects to enroll about 30 patients total.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Enrollment target
~30 participants
Started
November 2023
Primary completion
October 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in October 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ting Deng, MD
Tianjin Medical University Cancer Institute and Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.